ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Peter Thompson sold 69,500 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $13.03, for a total value of $905,585.00. Following the completion of the sale, the director now owns 83,695 shares of the company’s stock, valued at $1,090,545.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
ARS Pharmaceuticals Price Performance
SPRY stock traded up $0.24 during midday trading on Monday, hitting $13.20. The company’s stock had a trading volume of 876,687 shares, compared to its average volume of 715,928. The company’s fifty day moving average price is $10.43 and its 200 day moving average price is $9.36. ARS Pharmaceuticals, Inc. has a twelve month low of $2.55 and a twelve month high of $16.50. The stock has a market capitalization of $1.28 billion, a P/E ratio of -24.92 and a beta of 0.87.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $2.00 million. Equities analysts expect that ARS Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on ARS Pharmaceuticals
Institutional Trading of ARS Pharmaceuticals
Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of ARS Pharmaceuticals by 37.0% in the first quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after buying an additional 779,969 shares during the last quarter. ClariVest Asset Management LLC acquired a new stake in ARS Pharmaceuticals during the 1st quarter valued at $2,790,000. SG Americas Securities LLC boosted its position in ARS Pharmaceuticals by 861.5% during the second quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock worth $950,000 after purchasing an additional 99,986 shares during the period. GSA Capital Partners LLP increased its holdings in shares of ARS Pharmaceuticals by 11.7% in the first quarter. GSA Capital Partners LLP now owns 128,889 shares of the company’s stock valued at $1,317,000 after purchasing an additional 13,545 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of ARS Pharmaceuticals by 5.9% in the fourth quarter. Franklin Resources Inc. now owns 4,098,497 shares of the company’s stock valued at $22,460,000 after purchasing an additional 229,988 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
See Also
- Five stocks we like better than ARS Pharmaceuticals
- Upcoming IPO Stock Lockup Period, Explained
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- What Are the U.K. Market Holidays? How to Invest and Trade
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- How to Capture the Benefits of Dividend Increases
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.